News & Updates

Finerenone confers consistent cardiorenal benefits in patients with CKD and T2D regardless of SGLT-2i use
Finerenone confers consistent cardiorenal benefits in patients with CKD and T2D regardless of SGLT-2i use
17 Nov 2021 byAudrey Abella

In patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) who were receiving the novel nonsteroidal MRA* finerenone, use of SGLT-2is** at baseline did not influence treatment outcomes, according to a subgroup analysis of the FIDELITY*** trial presented at ASN 2021.

Finerenone confers consistent cardiorenal benefits in patients with CKD and T2D regardless of SGLT-2i use
17 Nov 2021
TAF rivals TDF for CHB suppression after orthotopic liver transplantation
TAF rivals TDF for CHB suppression after orthotopic liver transplantation
17 Nov 2021